EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and ...
Morning Overview on MSN
Disabling a single protein called NFIL3 kept CAR T-cells fighting tumors longer in a screen of 400 transcription factors
Researchers screening roughly 400 transcription factors found that disabling a single protein, NFIL3, allowed CAR T-cells to ...
Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, today announced the successful dosing of the first patients across multiple ...
T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to ...
New research from the Snow Center for Immune Health is challenging long-held assumptions about autoimmune disease, revealing ...
A new study reveals a possible way to make CAR T-cell therapy more durable and effective by targeting a single gene-regulating protein.
Researchers found that lowering MHC I can expose cancerous or foreign cells to CD4+ T cell attack, reshaping assumptions about immune targeting.
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ...
CAR T-cell therapy has been hugely successful in treating certain types of tumours, and stiffening up cancer cells beforehand could make it even more effective ...
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.
T cells are some of the immune system's most important warriors. They can stop tumor growth and even fight off severe ...
Engineered cell products such as CAR T cells have demonstrated considerable therapeutic potential. Two studies in Science report new avenues to expand the applications of synthetic cell therapies – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results